Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2019 Earnings and Company Update
24 Octobre 2019 - 2:00PM
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing
company focused on developing curative therapeutics using
CRISPR/Cas9 technology both in vivo and ex vivo, will present third
quarter 2019 results and operational highlights in a conference
call on October 31, 2019 at 8 a.m. ET.
To join the call:
- U.S. callers should dial 888-208-1711 and use conference ID#
7693636, approximately five minutes before the call.
- International callers should dial +1 856-344-9299 and use
conference ID# 7693636, approximately five minutes before the
call.
A replay of the call will be available through the Events and
Presentations page of the Investor Relations section of the
company’s website at www.intelliatx.com, beginning on October 31,
2019 at 12 p.m. ET.
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company
focused on developing proprietary, curative therapeutics using the
CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology
has the potential to transform medicine by permanently editing
disease-associated genes in the human body with a single treatment
course, and through improved cell therapies that can treat cancer
and immunological diseases, or can replace patients’ diseased
cells. The combination of deep scientific, technical and clinical
development experience, along with its leading intellectual
property portfolio, puts Intellia in a unique position to unlock
broad therapeutic applications of the CRISPR/Cas9 technology and
create a new class of therapeutic products. Learn more about
Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com and follow
us on Twitter @intelliatweets.
Intellia Contacts:
Investor
Contact:
Lina Li Associate Director, Investor Relations +1
857-706-1612lina.li@intelliatx.com
Media Contact:Jennifer Mound Smoter Senior Vice
President, External Affairs & Communications +1 857-706-1071
jenn.smoter@intelliatx.com
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024